Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 6.84%
As of Tuesday, July 21, SAB Biotherapeutics, Inc.’s SABS share price has surged by 6.84%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Commentary & Analysis
Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Down 5.18%
As of Friday, July 10, SAB Biotherapeutics, Inc.’s SABS share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Michael Rose
Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 5.74%
As of Wednesday, June 17, SAB Biotherapeutics, Inc.’s SABS share price has surged by 5.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 21.62%
As of Monday, June 15, SAB Biotherapeutics, Inc.’s SABS share price has surged by 21.62%, which has investors questioning if this is right time to sell.Jenna Brashear
Why SAB Biotherapeutics, Inc.’s (SABS) Stock Is Up 24.02%
As of Monday, June 15, SAB Biotherapeutics, Inc.’s SABS share price has surged by 24.02%, which has investors questioning if this is right time to sell.Omar Beirat
Financial Summary
| Share Statistics | SABS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $338.5 | $289.2 | 32% |
|
| Shares Out (Mil) | 79.8 | 54.1 | 58% |
|
| Institutional Ownership | 98.6% | 93.1% | 80% |
|
| Float (Mil) | 62.0 | 42.2 | 52% |
|
| Beta | 0.53 | 0.94 | 30% |
|
| Avg Daily Volume (000s) | 278 | 451 | 50% |
|
| Price Change (52-week) |
60.4% | 59.8% | 84% |
|
| Growth | SABS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (7.9%) | (10.1%) | 31% |
|
| EPS (5yr) | (16.1%) | 15.9% | 17 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (49.6%) | (15.6%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.269) | ($1.163) | ($0.954) | |
| Month Ago EPS | ($0.305) | ($1.279) | ($0.981) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 2 | 1 | 0 | |
| Three Months Ago EPS | ($0.240) | ($1.080) | ($0.893) | |
| Year/Year Chg | (4.6%) | 46.5% | 6.7% | |
| Financials | SABS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($13) | ($43) | 27% |
|
| EPS (TTM) | ($0.453) | ($1.500) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($54) | ($31) | 9% |
|
| Net Cash Flow (TTM) (Mil) | $5 | $2 | 52% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $4 | 24% |
|
| Enterprise Value (Q1) (Mil) | $246 | $190 | 27% |
|
| Valuation | SABS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.45 | 2.84 | 37% |
|
| P/E | na | 20.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | SABS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (9.5%) | (47.8%) | 26% |
|
| ROE | (11.3%) | (55.0%) | 27% |
|
| Liabilities to Assets | 9.8% | 29.7% | 6% |
|
| F-Score | 2 | 3 | 7% |
|
SAB Biotherapeutics, Inc. did not pass any screens on 9/3/2026.
